

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HILZINGER KURT J</u>  (Last) (First) (Middle) <u>C/O ONCOBIOLOGICS, INC</u> <u>7 CLARKE DRIVE</u>  (Street) <u>CRANBURY NJ 08521</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Oncobiologics, Inc. [ ONS ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/28/2016</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person  Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/28/2016		J <sup>(1)</sup>		11,633 <sup>(1)</sup>	A	\$0.00 <sup>(1)</sup>	11,633	D	
Common Stock	11/30/2016		J <sup>(2)</sup>		6,885 <sup>(2)</sup>	A	\$0.00 <sup>(2)</sup>	18,518	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrant (Right to Buy)	\$0.01	11/28/2016		J <sup>(3)</sup>		12,036 <sup>(3)</sup>		(4)	11/08/2019	Common Stock	12,036 <sup>(3)</sup>	\$0.00	12,036 <sup>(3)</sup>	D	

**Explanation of Responses:**

- Represents the receipt of 11,633 shares of Common Stock in a pro rata distribution for no consideration from Proximare Lifesciences Fund LLC, of which the reporting person is a member.
- Represents the receipt of 6,885 shares of Common Stock in a pro rata distribution for no consideration from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member.
- Represents the receipt of (i) a Warrant to purchase 7,561 from Proximare Lifesciences Fund LLC, of which the reporting person is a member, and (ii) a Warrant to purchase 4,475 from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member, in a pro rata distribution for no consideration.
- Immediately exercisable.

**Remarks:**

/s/ Lawrence A. Kenyon, 11/30/2016  
Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.